BIG PHARMA at work
Home
Shortages in Essential Drugs--Big PhARMA at work
MOST drugs are from China and India
Medical Device Makers cannot be sued, Supreme Court Rules
Ghost writing the norm for over a decade
journal articles are advertising dressed as science--examples
Top 10 Drug Recalls and Warnings of 07
FDA Fraud Program
Big PhARMA ghost writes journal articles
Big PHARMA pays generic manufacturers to not ...
New CANCER drugs add little to life expectancy--why
Big Pharma influences the DSM manual
Most Drugs Now are both Imported and not Tested for Purity
Slash taxes or we move our facilities
RU-486 comes from China, now--more tainted drugs
Antidepressants Proven useless for most
Heart Medication kills 22,000 in 2 years
Statin combination Vytorin doesn't work, etc.
Off Label Drug Pushers
0ff Prescription Market Law Eli Lilly violates for Zyprexa
Price Gouging for Orphan Drugs
Marketing department ran massive drug trial for VIOXX
Direct to consumer spending on the rise
Pharma Lobby and Democrats
U.S. Pharma Moves to China and India
Research and Production moves to China and India
Cancer Generic Drug Shortage increases sales of patented drugs

Slash taxes or we move our facilities

 

The fundamental incentive of corporations is to maximize profits.  Developed nations have through treaties adopted the neoliberal rules, and thereby have given their ability to regulate markets. Without controls (the neoliberal scheme) including market incentives such as tariffs which make give a competitive advantage to local industries, companies move production facilities and offices to nations with cheaper labor, lowest taxes, and less environmental laws.  Thus the major exodus in the US and other developed nations (all of whom have adopted the neoliberal economic policies.  Free to move entails that the industries can pressure governments to give them special concessions with the threat of outsourcing—and often then outsource after they receive this concession.

Slash tax take: drug companies

Siobhain Ryan, May 02, 08

http://www.theaustralian.news.com.au/story/0,25197,23632058-5013871,00.html

The Australian is a Merdock owned Australian news service. 

AUSTRALIA must slash its company tax rate by one-third within three years to stop drug company production lines moving offshore, the pharmaceutical industry has told a government review.

 

Cutting the corporate tax rate from 30per cent to 20per cent would take Australia halfway towards the low-tax regimes of China, India and others, and give it a chance of competing, Medicines Australia said.

The document, one of more than 600 submitted to Industry Minister Kim Carr's review of programs supporting industry, warned that without action, multinational drug companies would follow the example of one of the world's biggest, Merck Sharp & Dohme.

Merck Sharp & Dohme scaled back manufacturing at its South Granville plant in Sydney's west this year at the cost of 60 jobs, demonstrating that Australia "has already lost these advantages or, at the very least, faces the real danger of losing them some time very soon", the submission said.

The pharmaceutical industry exported nearly $4billion worth of products last year and spent $450million on research and development. But it has lost access to many of the government programs that pumped hundreds of millions of dollars into the sector between 1988 and 2004.

Kevin Rudd lent some support to the call for corporate tax reform at last month's 2020 Summit, but he has been wary of making detailed commitments. A spokeswoman for Senator Carr yesterday declined to comment on Medicines Australia's proposals before the completion of the review.

 

 

Guess what happens when you buy your drugs from China already packaged, and out source drug testing.  Answer:  don’t need major U.S. facility—just like what happened to Detroit.

 

http://www.globest.com/news/1115_1115/detroit/169110-1.html

 

Pfizer Inc. Sees Interest in 2M-SF Mixed Site

 

By Robert Carr March 17, 2008  09:46am

 

ANN ARBOR, MI-Pfizer Inc. has had more than 60 tours of its 2.2-million-sf site that it plans to vacate by 2009 {almost empty now}, including a visit from Cleveland-based developer Forest City Enterprises Inc. The drug maker, based in New York City, announced last spring that it would be closing down the Ann Arbor property, which has 28 buildings spread over 175 acres, and sending some employees elsewhere. The company is cutting 10,000 jobs worldwide, including most of the jobs here.

A Forest City spokeswoman tells GlobeSt.com that Michael Rosen, SVP for new business development of the company’s Science and Technology Group, did take a look at the property. However, she refused to provide more details, and Rosen could not be reached for comment. “Touring sites is something we do all the time across the country,” she says. “We really don’t have anything to announce.” The company has bought Pfizer properties before, including a one-million-sf site in Skokie, IL, creating a business park where Rosen himself is now based.

A spokesman for Pfizer tells GlobeSt.com that he can’t comment on any tours of the site, but confirmed there have been dozens of companies, some who have toured more than once. The company has been working with Staubach brokers since June. “We’ve had a good response to our marketing effort,” the spokesman says. “We’re still early in the process.”

Another rumor is that the University of Michigan, which owns adjacent properties, may buy the property or go in on the land in a joint venture. University officials reportedly admitted an interest, but would not comment further.

The Pfizer spokesman says the company wants to be a good neighbor. “We’ve certainly have had conversations with them to gauge their interest.”

The company has transferred most of the employees from the 28 buildings. “We’ve transferred most of the research and development work to other locations,” the spokesman says. “We’re at about a 330-person headcount, down from 2,100, people when we were operational.” The space breakdown is 720,000 sf of office, 750,000 sf of laboratory and other research space, and a 234,000 sf manufacturing facility. The property can be subdivided or sold as whole, he says.

Pfizer is also closing plants in Kalamazoo, and two manufacturing sites in Brooklyn, NY and Omaha, NE. “We did a global assessment for all our operations worldwide in 2006, and realized we needed to have a more streamlined global operation,” the spokesman says. “We’ll still have a very large presence in Kalamazoo, we’re keeping our largest manufacturing site.” The firm will close Ann Arbor completely by the end of the year.

Streamlined global operation” means, it is cheaper to buy the drugs prepackaged from China.